| Literature DB >> 27912057 |
Timothy R Sampson1, Justine W Debelius2, Taren Thron3, Stefan Janssen2, Gauri G Shastri3, Zehra Esra Ilhan4, Collin Challis3, Catherine E Schretter3, Sandra Rocha5, Viviana Gradinaru3, Marie-Francoise Chesselet6, Ali Keshavarzian7, Kathleen M Shannon8, Rosa Krajmalnik-Brown4, Pernilla Wittung-Stafshede5, Rob Knight9, Sarkis K Mazmanian10.
Abstract
The intestinal microbiota influence neurodevelopment, modulate behavior, and contribute to neurological disorders. However, a functional link between gut bacteria and neurodegenerative diseases remains unexplored. Synucleinopathies are characterized by aggregation of the protein α-synuclein (αSyn), often resulting in motor dysfunction as exemplified by Parkinson's disease (PD). Using mice that overexpress αSyn, we report herein that gut microbiota are required for motor deficits, microglia activation, and αSyn pathology. Antibiotic treatment ameliorates, while microbial re-colonization promotes, pathophysiology in adult animals, suggesting that postnatal signaling between the gut and the brain modulates disease. Indeed, oral administration of specific microbial metabolites to germ-free mice promotes neuroinflammation and motor symptoms. Remarkably, colonization of αSyn-overexpressing mice with microbiota from PD-affected patients enhances physical impairments compared to microbiota transplants from healthy human donors. These findings reveal that gut bacteria regulate movement disorders in mice and suggest that alterations in the human microbiome represent a risk factor for PD. Copyright ÂEntities:
Keywords: Parkinson’s disease; gut-brain axis; microbiome; microglia; mouse model; short chain fatty acids; synuclein
Mesh:
Substances:
Year: 2016 PMID: 27912057 PMCID: PMC5718049 DOI: 10.1016/j.cell.2016.11.018
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582